Tritonpoint Wealth, LLC Halozyme Therapeutics, Inc. Transaction History
Tritonpoint Wealth, LLC
- $1.04 Trillion
- Q2 2024
A detailed history of Tritonpoint Wealth, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Tritonpoint Wealth, LLC holds 6,745 shares of HALO stock, worth $363,218. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,745
Previous 6,764
0.28%
Holding current value
$363,218
Previous $250 Million
41.05%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
487Shares Held
123MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$949 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$694 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$313 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$218 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$200 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.5B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...